1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shilpa Medicare Limited

Shilpa Medicare Limited

SHILPAMED.BO
Shilpa Medicare LimitedIN flagBombay Stock Exchange
591.00
INR
-4.65
- -
57.79BMarket Cap
Shilpa Medicare Limited
SHILPAMED.BO
(Bombay Stock Exchange)

Recent

price

591.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
20.98
22.06
25.24
37.25
38.02
41.34
46.86
46.51
42.26
55.13
55.21
68.24
60.11
66.34
66.06
- -
79.3
Revenue per Share
3.57
2.86
3.22
5.14
4.8
7.03
6.91
6.53
6.88
9.58
9.06
3.63
-1.87
1.84
4.02
- -
12.54
Basic EPS, GAAP
1.42
3.93
2.97
4.76
4.48
8.35
-5.11
-5.78
-4.45
-13.79
-18.85
-13.57
-2.69
-2.76
-5.72
- -
- -
Free Cash Flow per Basic Share
0.13
0.15
0.17
0.25
0.29
0.69
0.35
0.45
- -
1.27
- -
0.54
0.55
- -
- -
- -
- -
Dividend per Share
7.77
9.8
12.21
16.8
20.7
26.74
32.7
37.46
43.89
52.2
61.31
62.96
58.17
60.05
0.5
- -
1.01
Book Value per Share
16.13
15.11
13.14
19
34.66
40.28
56.37
58.53
61.44
65.66
68.09
81.81
74.2
74.01
92.38
- -
97.75
Tangible Book Value per Share
138
144
147
147
154
154
156
161
163
163
163
167
174
174
195
- -
194
Basic Weighted Avg Shares
2,903
3,182
3,713
5,482
5,839
6,375
7,301
7,491
6,890
8,989
9,002
11,400
10,434
11,516
12,864
15,389
15,381
Sales/Revenue/Turnover
20.06
15.75
14.51
18.04
18.06
21.74
18.53
15.35
16.92
19.21
13.25
11.04
-0.44
11.62
18.95
24.43
21.53
Operating Margin (%)
130
144
153
232
214
231
306
372
421
438
540
798
955
1,079
1,130
1,197
1,028
Depreciation Expense
493
412
473
757
737
1,083
1,076
1,052
1,123
1,562
1,478
607
-325
319
783
2,433
2,433
Net Income, GAAP
22.83
22.92
16.72
21.27
32.66
25.38
28.7
24.79
19.29
17.81
25.04
40.76
- -
41.19
36
17.61
17.6
Effective Tax Rate (%)
17
12.96
12.75
13.8
12.62
16.99
14.74
14.05
16.29
17.37
16.42
5.32
-3.12
2.77
6.09
15.81
15.82
Profit Margin (%)
982
667
882
669
1,465
1,353
4,930
4,061
2,916
2,130
2,993
2,757
-149
1,827
3,114
2,617
2,617
Working Capital
114
51
705
675
163
21
1,425
681
811
1,671
4,758
3,547
2,906
5,614
2,332
1,851
1,851
LT Debt
2,262
2,808
3,291
4,065
5,461
7,121
9,841
10,798
11,900
13,215
14,675
18,111
17,744
17,923
23,637
25,912
25,912
Total Equity
19.41
12.31
11.13
15.73
12.13
14.28
9.5
6.91
7.05
9.1
4.41
3.09
- -
2.95
5.48
9.99
8.8
Return on Invested Capital (%)
41.26
22.91
18.38
22.7
19.56
24.87
17.96
14.22
13.91
15.11
10.79
4.78
- -
4.3
11.77
53.92
25.85
Return on Capital (%)
88.2
33.15
29.49
35.45
26.08
29.68
23.34
18.92
17.02
19.93
15.97
5.91
-3.16
3.11
14.88
1,658.74
43.2
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
4,022
- -
4,747
LT Borrowings
1,896
- -
1,838
LT Finance Leases
14
- -
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
196
- -
196
Market Capitalization
73,788
62,340
67,628

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10,588
- -
11,098
Cash, Cash Equivalents & STI
536
- -
917
Accounts Receivable, Net
4,269
- -
5,188
Inventories
4,449
- -
3,668
Total Current Liabilities
7,803
- -
8,481
Payables & Accruals
- -
- -
- -
ST Debt
4,022
- -
4,747
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.41%
12.78%
9.62%
Free Cash Flow
3.48%
-9%
-74.46%
Net Income, GAAP
-1.66%
-10.83%
210.77%
Sales/Revenue/Turnover
9.96%
11.98%
19.62%
Total Cash Common Dividend
- -
- -
2.43%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,602
3,130
2,868
2,912
11,516
2025
2,925
3,438
3,193
3,308
12,864
2026
3,215
3,700
4,097
4,370
15,389

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.09
0.26
- -
1.84
2025
0.73
0.92
1.63
0.74
4.02
2026
2.4
2.25
2.36
5.51
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PLx Pharma Inc. (PLXP)
Tasly Pharmaceutical Group Co., Ltd (600535.SS)
MGC Pharmaceuticals Limited (MXC.L)
Benchmark Holdings plc (BMK.L)
Cannabis Bioscience International Holdings, Inc. (CBIH)
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
Business
Shilpa Medicare Limited, founded in 1987 and headquartered in Raichur, Karnataka, India, manufactures and sells active pharmaceutical ingredients, generic formulations, and biologics primarily in oncology and other therapeutic areas including leukemia, breast cancer, multiple myeloma, and non-oncology indications such as psoriasis, multiple sclerosis, and chronic hepatitis B; core products encompass APIs like anastrozole, capecitabine, gemcitabine HCl, and lenalidomide, formulations including injectable dosage forms (azacitidine, bendamustine, bortezomib, busulfan, clofarabine, decitabine, docetaxel, gemcitabine, irinotecan, melphalan, pemetrexed, zoledronic acid), oral solids (apremilast, bicalutamide, capecitabine, dimethyl fumarate, erlotinib, imatinib, pirfenidone, prucalopride, thalidomide, tenofovir alafenamide, lenvatinib, teriflunomide, fingolimod, sunitinib), and biologics such as monoclonal antibodies, biosimilars, vaccines, and recombinant human albumin; the company also provides contract development and manufacturing organization services covering chemical development, high-potent APIs, peptide synthesis, polymer development, continuous flow chemistry, and formulation development for regulated markets in the US, Europe, and MENA regions through five manufacturing facilities in India and subsidiaries like Shilpa Biologicals Pvt Ltd and Koanna International FZ LLC in UAE. Recent developments include a 2025 joint venture in Saudi Arabia via Koanna with Pharma Pharmaceutical Industries for bulk formulations supply, local manufacturing, and technology transfer aligned with Vision 2030; an exclusive distribution agreement with Orion Corporation for recombinant human albumin in Europe; approval of a 1:1 bonus share issue and planned Q3 launch of NorUDCA, India's first-in-class therapy for non-alcoholic fatty liver disease; divestment of a 31% stake in joint venture Sravathi Advance Process Technologies for INR 496 million; strategic investment by subsidiary Shilpa Pharma Inc. in Alveolus Bio; capacity expansions for key APIs like UDCA, new dedicated blocks for oligonucleotides commercializing in FY26, and mammalian-based projects in biologics and food sectors.